Literature DB >> 21226637

Treatment of chronic myeloid leukemia when imatinib fails.

Rüdiger Hehlmann1, Susanne Jung-Munkwitz, Susanne Saussele.   

Abstract

INTRODUCTION: Imatinib failure represents a major clinical challenge in the management of chronic myeloid leukemia. AREAS COVERED: Definition of failure, its causes, the various approaches to the treatment of imatinib failure such as imatinib dose escalation, second-generation tyrosine kinase inhibitors and stem cell transplantation, and monitoring of residual disease are covered in this review. Selected investigational agents and the management of blast crisis are also reviewed. After reading the review the reader will understand how to manage imatinib failure. EXPERT OPINION: Imatinib failure can be managed in most cases by a careful appraisal of its causes and a rational selection of treatment options.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21226637     DOI: 10.1517/14656566.2011.533169

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.

Authors:  Tomas Radivoyevitch; Lynn Hlatky; Julian Landaw; Rainer K Sachs
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

2.  Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.

Authors:  L A Tobin; C Robert; A P Rapoport; I Gojo; M R Baer; A E Tomkinson; F V Rassool
Journal:  Oncogene       Date:  2012-05-28       Impact factor: 9.867

3.  c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Authors:  Nidal Muvarak; Shannon Kelley; Carine Robert; Maria R Baer; Danilo Perrotti; Carlo Gambacorti-Passerini; Curt Civin; Kara Scheibner; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2015-03-31       Impact factor: 5.852

4.  Combinational treatment of TPEN and TPGS induces apoptosis in acute lymphoblastic and chronic myeloid leukemia cells in vitro and ex vivo.

Authors:  Miguel Mendivil-Perez; Marlene Jimenez-Del-Rio; Carlos Velez-Pardo
Journal:  Med Oncol       Date:  2022-05-17       Impact factor: 3.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.